Cynosure Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Cynosure Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,312	Closed	-$422K	–	25
2018 Q2	$422K	Hold	6,312	–	–	0.11%	130
2018 Q1	$367K	Buy	+6,312	New	+$401K	0.09%	151

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cynosure Advisors's ANIP Position: Q3 2018 in Review

Cynosure Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2018, closing a stake of 6,312 shares — an estimated $422K sold.

Cynosure Advisors first reported a position in ANIP in Q1 2018 and held it in 2 quarters. The position peaked at $422K in Q2 2018. 173 funds tracked by Wall St. Rank hold ANIP as of Q3 2018.

Cynosure Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Cynosure Advisors sold 6,312 ANI Pharmaceuticals shares in Q3 2018, an estimated $422K.
Cynosure Advisors first reported a position in ANI Pharmaceuticals in Q1 2018 and held it in 2 quarters.
Cynosure Advisors's ANI Pharmaceuticals position peaked at $422K in Q2 2018.
173 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2018.

Based on Cynosure Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.